Core Competitiveness
As a global professional supplier of pharmaceutical materials, we leverage our deeply integrated global presence and localized services to build an end-to-end controllable supply chain system from laboratory research to commercial production, with R&D at the core. Through continuous process innovation and extensive technological expertise, we ensure high-quality and stable supply of every batch of APIs and intermediates, helping clients navigate the complex market environment and supply chain challenges.
R&D-Driven Supply Chain
Strong R&D Capabilities Ensure Supply Chain Reliability from the Source
Our 100+ R&D team, led by PhDs from Tsinghua and Peking University, leverages decades of process data to overcome critical synthetic and technological barriers, ensuring process robustness and supply continuity from the source.
Flexible Process Development Enhances Supply Chain Resilience
By designing non-infringing routes, achieving seamless scale-up from grams to tons, and optimizing key steps for safety and cost efficiency, we ensure highly adaptable processes that enhance supply chain flexibility for clients at various stages.
Green Efficiency and Engineering Optimization Enable Sustainable Supply Stability
By optimizing materials and pathways, we reduce synthesis risks by over 30% and significantly improve yields. Combined with process safety testing and engineering simulations, we build an efficient, safe, and green production system to provide a solid foundation for long-term supply stability.
Vertical Integration: Building a Self-Controlled Supply Chain for Pharmaceutical Materials
We implement a deep “backward integration” strategy to achieve self-control and efficient supply of key pharmaceutical materials, building end-to-end in-house capabilities from R&D and pilot to commercial production, thereby ensuring a secure, stable, and resilient supply chain.
In-House Production & Joint Venture Collaboration
Key materials are produced in GMP-compliant self-operated bases, supported by dedicated R&D teams for continuous process optimization to ensure stable supply of critical items. We also establish joint venture production bases with high-quality partners through core technology transfer, expanding integration capacity and enhancing supply chain flexibility.
Multi-Hub Capacity & Intelligent Supply Network
With dual hubs in Chongqing/Weifang and logistics nodes covering 90% of export markets (Japan, EU, US), we provide end-to-end coverage from R&D to commercialization. A multi-faceted capacity layout and intelligent inventory mechanisms enable rapid response to market fluctuations. Real-time risk control and emergency systems support quick backup capacity activation, with core processes independently controlled to ensure seamless capacity transition.
End-to-End Infrastructure & Global Resource Integration
With 4 self-operated production bases, 1000+ reactors (including 400+ specialized units), we support a wide range of specialized reactions from -78℃ cryogenic conditions to high temperature/pressure environments, enabling efficient production across 50L-6300L scales. Backed by national-level chemical parks, ton-scale pilot lines, and rigorous process safety assessments, we ensure reliable technology transfer. Our network of 300+ core suppliers and 1000+ partners enables one-stop raw material sourcing and 24/7 multilingual technical support, ensuring global supply stability and cost optimization.
Supply Chain Integrity and Compliance Commitment
With strong top-down management support for supply chain strategy, we adhere to stringent environmental, safety, and quality compliance standards, and maintain excellent audit records including US FDA. We conduct regular supplier audits, possess deep penetration in global pharmaceutical raw material markets, and provide end-to-end logistics management over transportation, warehousing, and import/export, building a reliable, transparent, and integrated global supply chain.
Quality and Compliance
Our quality management system strictly adheres to authoritative global standards, including GMP, ICH Q7/Q9/Q10, and 21 CFR 210/211, ensuring that our pharmaceutical raw material production, from source to finished product, meets the stringent requirements of major global markets.
Our compliance capabilities have been widely validated by the market. To date, we have successfully passed over 100 audits for domestic and international clients, as well as on-site inspections by numerous international regulatory bodies, including the US FDA, Australian TGA, South Korea MFDS, and EU member state drug regulatory authorities.
Partnerships
We break through traditional supply-demand relationships and establish a deep, collaborative development model with our clients, enabling efficient pharmaceutical product launches.
Joint Applications
Jointly apply for new drug and generic drug approval numbers with pharmaceutical manufacturers.
Approval Transfers
Assist with the transfer or assignment of drug approvals.
Manufacturing Services
Undertake the production of new product validation batches, as well as contract manufacturing of related products and intermediates.
Long-Term Agreements
Provide long-term supply agreements to ensure a stable supply chain.
